ADA and chronic granulomatous disease: Unlike trials with gammaretroviral vectors in other diseases like X-linked SCID (Hacein-Bey-Abina et al., 2008; Howe et al., 2008), chronic granulomatous disease (Ott et al., 2006) and Wiskott–Aldrich Syndrome (Trobridge, 2011), the cumulative experience of these studies for ADA-SCID (Aiuti et al., 2009; Ferrua et al., 2010; Montiel-Equihua et al., 2012) did not reveal leukemic or oncogenic events, indicating that ADA-SCID gene therapy has a favorable risk/benefit profile.